Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.13, $0.02 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $49 million versus the consensus estimate of $48.05 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.